Apyx Medical Corporation
Apyx Medical Corporation (APYX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
apyx · stock forecast · 9 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 9 Wall Street analysts in the past 3 months
Buy
9 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$6.00
Consensus
$6.00
+25.8% upside
Low
$6.00
Median: $6 · Last Close: $4.77
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $4.93 | ↑ 3.41% |
1-day model range: $4.87–$5. Peak: $5 (+3.41%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $10 | +120.0% |
| 2028 | $17 | +252.0% |
| 2029 | $22 | +357.6% |
| 2030 | $25 | +426.2% |
| 2031 | — | +465.7% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · APYX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-03-11 | Craig-Hallum | Maintains | Buy→Buy |
| 2026-03-11 | BTIG | Upgrade ↑ | Neutral→Buy |
| 2025-11-12 | Citizens | Upgrade ↑ | Market Perform→Market Outperform |
| 2023-11-10 | Stephens & Co. | Maintains | Overweight→Overweight |
| 2023-08-11 | Piper Sandler | Maintains | Overweight→Overweight |
| 2023-06-15 | Lake Street | Maintains | Buy→Buy |
| 2023-05-24 | JMP Securities | Maintains | Market Perform→Perform |
| 2023-05-12 | Lake Street | Maintains | Buy→Buy |
| 2022-08-12 | Piper Sandler | Maintains | Overweight→Overweight |
| 2022-07-19 | Lake Street | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Apyx Medical Corporation (APYX) stock. Of the recent 20 rating actions, 2 were upgrades and 0 were downgrades. 9 analysts currently cover APYX.
Analyst Recommendation Trends
APYX analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$47M
↓ 20.6% YoY
Revenue Next Year
$52M
↑ 10.5% YoY
EPS This Year
$-0.71
EPS Next Year
$-0.30
↓ 57.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast APYX EPS of $-0.71 for the current fiscal year, based on estimates from 2 analysts. The APYX revenue forecast is $47M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The APYX stock forecast is supported by two independent data sources: analyst consensus ratings from 9 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus APYX price target is $6.00 (+25.8% upside), with an analyst consensus of Buy.
The APYX short-term stock prediction for tomorrow is $4.93 (+3.41%). The APYX stock price prediction for 2027 estimates an average of $10. The APYX stock prediction for 2030 projects a range of $21–$29.
Apyx Medical Corporation trades on NASDAQ under the ticker APYX. The APYX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 89% of covering analysts.
Frequently asked questions
APYX forecast · 8 questionsAccording to 9 Wall Street analysts, the average 12-month APYX price target is $6.00, with a high forecast of $6.00 and a low of $6.00. The median price target is shown in the chart above when available. This implies +25.8% potential upside from the current price of $4.77.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.